PF-06873600

SKU: orb1298913

Description

PF-06873600 is an orally bioavailable, selective CDK2/4/6 inhibitor with low nanomolar Ki values. It exhibits antineoplastic activity and has been investigated in preclinical studies for cancer research, demonstrating effects in both cellular and animal models of various malignancies.

Research Area

Cell Biology

Key Properties

• CAS Number: 2185857-97-8
• MW: 471.52
• Purity: 99.58% (May vary between batches)
• Formula: C₂₀H₂₇F₂N₅O₄S
• SMILES: C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(C)(=O)=O)ncc2cc(C(F)F)c1=O
• Target: CDK
• Solubility: DMSO:150 mg/mL (318.12 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (7 mM)

Bioactivity

• Target IC50:
  CDK6:0.16 nM (Ki)|CDK4:0.13 nM (Ki)|CDK2:0.09 nM (Ki)
• In Vitro:
  PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CDK2, PF 06873600, PF06873600, PF-06873600, PF3600

Compound Identifiers

PubChem CID

134247638